19 April 2021
Incanthera plc
("Incanthera" or the "Company")
Directors dealings
Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the "Transactions").
The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:
Employee Company Position Transaction Volume Purchase Price
Tim McCarthy Chairman 49,382 13.50p
Simon Ward CEO 51,593 13.50p
Pawel Zolnierzyck COO 11,307 13.20p
Laura Brogden CFO 15,057 13.15p
Suzanne Brocks Head of Communications 50,000 13.00p
Total Shareholdings following the Transactions:
Employee Company Position Total Shareholding % of Share Capital
Tim McCarthy Chairman 3,931,646 5.31%
Simon Ward CEO 2,704,199 3.65%
Pawel Zolnierzyck COO 669,544 0.90%
Laura Brogden CFO 46,034 0.06%
Suzanne Brocks Head of Communications 325,594 0.44%
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
For further enquiries:
| Incanthera plc
Tim McCarthy, Chairman
Simon Ward, Chief Executive Officer
Suzanne Brocks, Head of Communications |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
|
| Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis/Mark Rogers |
+44 (0) 20 7213 0880 |
|
|
|
| Broker: Stanford Capital Partners Ltd Patrick Claridge/Tom Price/John Howes/Bob Pountney |
+44 (0) 20 3815 8880 |
Notes to Editors
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities/ person closely associated with them.
| 1. |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||||||||
|
|
Name
|
|
||||||||||||
| 2. |
Reason for the notification |
|||||||||||||
| a) |
Position/status |
As above |
||||||||||||
| b) |
Initial notification/Amendment |
Initial Notification |
||||||||||||
| 3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
| a) |
Name |
Incanthera plc |
||||||||||||
| b) |
LEI |
2138002HEV4UFBOEXQ97 |
||||||||||||
| 4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
| a) |
Description of the financial instrument |
Ordinary Shares of 0.02p |
||||||||||||
| b) |
Identification code |
GB00BGL7YW15 |
||||||||||||
| c) |
Nature of the transactions |
Purchase of Ordinary Shares |
||||||||||||
| d) |
Volumes and Prices |
|
||||||||||||
| e) |
Aggregated information - Aggregated volume - Price |
|
||||||||||||
| f) |
Date of the transactions |
15 April 2021 |
||||||||||||
| f) |
Place of the transactions |
AQSE Growth Market, UK |
||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.